Literature DB >> 20450868

Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.

Govind Ragupathi1, Payal Damani, Kai Deng, Michelle M Adams, Jianfeng Hang, Constantine George, Philip O Livingston, David Y Gin.   

Abstract

The saponin fraction QS-21 from Quillaja saponaria has been demonstrated to be a potent immunological adjuvant when mixed with keyhole limpet hemocyanin conjugate vaccines, as well as with other classes of subunit antigen vaccines. QS-21 adjuvant is composed of two isomers that include the apiose and xylose forms in a ratio of 65:35, respectively. The chemical syntheses of these two isomers in pure form have recently been disclosed. Herein we describe detailed in vivo immunological evaluations of these synthetic QS-21 isomeric constituents, employing the GD3-KLH melanoma antigen. With this vaccine construct, high antibody titers against GD3 ganglioside and KLH were elicited when GD3-KLH was co-administered with adjuvant, either as the individual separate synthetic QS-21 isomers (SQS-21-Api or SQS-21-Xyl), or as its reconstituted 65:35 isomeric mixture (SQS-21). These antibody titer levels were comparable to that elicited by vaccinations employing naturally derived QS-21 (PQS-21). Moreover, toxicities of the synthetic saponin adjuvants were also found to be comparable to that of naturally derived PQS-21. These findings demonstrate unequivocally that the adjuvant activity of QS-21 resides in these two principal isomeric forms, and not in trace contaminants within the natural extracts. This lays the foundation for future exploration of structure-function correlations to enable the discovery of novel saponins with increased potency, enhanced stability, and attenuated toxicity. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20450868      PMCID: PMC2882175          DOI: 10.1016/j.vaccine.2010.04.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

Authors:  Kai Deng; Michelle M Adams; Payal Damani; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

2.  Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity.

Authors:  D J Marciani; J B Press; R C Reynolds; A K Pathak; V Pathak; L E Gundy; J T Farmer; M S Koratich; R D May
Journal:  Vaccine       Date:  2000-07-15       Impact factor: 3.641

3.  Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.

Authors:  S K Kim; G Ragupathi; C Musselli; S J Choi; Y S Park; P O Livingston
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

4.  Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.

Authors:  S Sasaki; K Sumino; K Hamajima; J Fukushima; N Ishii; S Kawamoto; H Mohri; C R Kensil; K Okuda
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  Studies on the synthesis of landomycin A: synthesis and glycosidation reactions of L-rhodinosyl acetate derivatives.

Authors:  W R Roush; C E Bennett; S E Roberts
Journal:  J Org Chem       Date:  2001-09-21       Impact factor: 4.354

6.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.

Authors:  S Zhang; C Cordon-Cardo; H S Zhang; V E Reuter; S Adluri; W B Hamilton; K O Lloyd; P O Livingston
Journal:  Int J Cancer       Date:  1997-09-26       Impact factor: 7.396

7.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens.

Authors:  S Zhang; H S Zhang; C Cordon-Cardo; V E Reuter; A K Singhal; K O Lloyd; P O Livingston
Journal:  Int J Cancer       Date:  1997-09-26       Impact factor: 7.396

8.  Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.

Authors:  P O Livingston; S Adluri; F Helling; T J Yao; C R Kensil; M J Newman; D Marciani
Journal:  Vaccine       Date:  1994-11       Impact factor: 3.641

9.  GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.

Authors:  F Helling; A Shang; M Calves; S Zhang; S Ren; R K Yu; H F Oettgen; P O Livingston
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

10.  Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.

Authors:  A M Carcaboso; R M Hernández; M Igartua; J E Rosas; M E Patarroyo; J L Pedraz
Journal:  Vaccine       Date:  2004-03-29       Impact factor: 3.641

View more
  10 in total

1.  Characterization of in vivo anti-rotavirus activities of saponin extracts from Quillaja saponaria Molina.

Authors:  Ka Ian Tam; Michael R Roner
Journal:  Antiviral Res       Date:  2011-04-23       Impact factor: 5.970

2.  Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.

Authors:  Pengfei Wang; Đani Škalamera; Xianwei Sui; Ping Zhang; Suzanne M Michalek
Journal:  ACS Infect Dis       Date:  2019-03-28       Impact factor: 5.084

Review 3.  Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.

Authors:  Govind Ragupathi; Jeffrey R Gardner; Philip O Livingston; David Y Gin
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

4.  Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes.

Authors:  Eric K Chea; Alberto Fernández-Tejada; Payal Damani; Michelle M Adams; Jeffrey R Gardner; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  J Am Chem Soc       Date:  2012-08-06       Impact factor: 15.419

5.  Synthesis of QS-21-based immunoadjuvants.

Authors:  Pengfei Wang; Qipu Dai; Punith Thogaripally; Ping Zhang; Suzanne M Michalek
Journal:  J Org Chem       Date:  2013-11-05       Impact factor: 4.354

Review 6.  Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.

Authors:  Sulana K Schroeder; Aurelie Joly-Amado; Marcia N Gordon; Dave Morgan
Journal:  J Neuroimmune Pharmacol       Date:  2015-11-04       Impact factor: 4.147

7.  Quillaja Saponin Variants with Central Glycosidic Linkage Modifications Exhibit Distinct Conformations and Adjuvant Activities.

Authors:  William E Walkowicz; Alberto Fernández-Tejada; Constantine George; Francisco Corzana; Jesús Jiménez-Barbero; Govind Ragupathi; Derek S Tan; David Y Gin
Journal:  Chem Sci       Date:  2016-01-15       Impact factor: 9.825

8.  cGAMP/Saponin Adjuvant Combination Improves Protective Response to Influenza Vaccination by Microneedle Patch in an Aged Mouse Model.

Authors:  Elena V Vassilieva; Song Li; Heorhiy Korniychuk; Dahnide M Taylor; Shelly Wang; Mark R Prausnitz; Richard W Compans
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 7.561

Review 9.  New vaccines against influenza virus.

Authors:  Young-Tae Lee; Ki-Hye Kim; Eun-Ju Ko; Yu-Na Lee; Min-Chul Kim; Young-Man Kwon; Yinghua Tang; Min-Kyoung Cho; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Clin Exp Vaccine Res       Date:  2013-12-18

10.  Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis.

Authors:  Alberto Fernández-Tejada; Derek S Tan; David Y Gin
Journal:  Acc Chem Res       Date:  2016-08-28       Impact factor: 22.384

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.